High-dose chemotherapy and autologous hematopoietic stem-cell rescue for treatment of relapsed and refractory Wilms tumor: Re-evaluating outcomes

Research output: Contribution to journalArticle

Abstract

Wilms tumor (WT) treatment regimens are curative for more than 80% of patients, but those with relapsed or refractory disease continue to have poor outcomes. High-dose chemotherapy followed by autologous stem cell rescue is often utilized although outcomes remain variable. We report on HD-ASCR outcomes in 24 patients with relapsed or refractory Wilms tumor. Three-year disease free and overall survival are 46% and 60%, respectively, which is similar to those reported for conventional salvage therapies. These outcomes suggest that conventional salvage therapies should be employed for relapsed and refractory WT rather than HD-ASCR.

Original languageEnglish (US)
Pages (from-to)316-321
Number of pages6
JournalPediatric Hematology and Oncology
Volume35
Issue number5-6
DOIs
StatePublished - Aug 18 2018

Fingerprint

Wilms Tumor
Hematopoietic Stem Cells
Salvage Therapy
Drug Therapy
Disease-Free Survival
Stem Cells
Therapeutics

Keywords

  • Autologous stem cell rescue
  • Wilms tumor
  • refractory
  • relapsed

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

@article{6fed498df40c4a31839ea5bc8896df16,
title = "High-dose chemotherapy and autologous hematopoietic stem-cell rescue for treatment of relapsed and refractory Wilms tumor: Re-evaluating outcomes",
abstract = "Wilms tumor (WT) treatment regimens are curative for more than 80{\%} of patients, but those with relapsed or refractory disease continue to have poor outcomes. High-dose chemotherapy followed by autologous stem cell rescue is often utilized although outcomes remain variable. We report on HD-ASCR outcomes in 24 patients with relapsed or refractory Wilms tumor. Three-year disease free and overall survival are 46{\%} and 60{\%}, respectively, which is similar to those reported for conventional salvage therapies. These outcomes suggest that conventional salvage therapies should be employed for relapsed and refractory WT rather than HD-ASCR.",
keywords = "Autologous stem cell rescue, Wilms tumor, refractory, relapsed",
author = "Jenna Rossoff and Tse, {William T.} and Duerst, {Reggie E} and Jennifer Schneiderman and Morgan, {Elaine R} and Morris Kletzel and Sonali Chaudhury",
year = "2018",
month = "8",
day = "18",
doi = "10.1080/08880018.2018.1532478",
language = "English (US)",
volume = "35",
pages = "316--321",
journal = "Pediatric Hematology and Oncology",
issn = "0888-0018",
publisher = "Informa Healthcare",
number = "5-6",

}

TY - JOUR

T1 - High-dose chemotherapy and autologous hematopoietic stem-cell rescue for treatment of relapsed and refractory Wilms tumor

T2 - Re-evaluating outcomes

AU - Rossoff, Jenna

AU - Tse, William T.

AU - Duerst, Reggie E

AU - Schneiderman, Jennifer

AU - Morgan, Elaine R

AU - Kletzel, Morris

AU - Chaudhury, Sonali

PY - 2018/8/18

Y1 - 2018/8/18

N2 - Wilms tumor (WT) treatment regimens are curative for more than 80% of patients, but those with relapsed or refractory disease continue to have poor outcomes. High-dose chemotherapy followed by autologous stem cell rescue is often utilized although outcomes remain variable. We report on HD-ASCR outcomes in 24 patients with relapsed or refractory Wilms tumor. Three-year disease free and overall survival are 46% and 60%, respectively, which is similar to those reported for conventional salvage therapies. These outcomes suggest that conventional salvage therapies should be employed for relapsed and refractory WT rather than HD-ASCR.

AB - Wilms tumor (WT) treatment regimens are curative for more than 80% of patients, but those with relapsed or refractory disease continue to have poor outcomes. High-dose chemotherapy followed by autologous stem cell rescue is often utilized although outcomes remain variable. We report on HD-ASCR outcomes in 24 patients with relapsed or refractory Wilms tumor. Three-year disease free and overall survival are 46% and 60%, respectively, which is similar to those reported for conventional salvage therapies. These outcomes suggest that conventional salvage therapies should be employed for relapsed and refractory WT rather than HD-ASCR.

KW - Autologous stem cell rescue

KW - Wilms tumor

KW - refractory

KW - relapsed

UR - http://www.scopus.com/inward/record.url?scp=85060596889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060596889&partnerID=8YFLogxK

U2 - 10.1080/08880018.2018.1532478

DO - 10.1080/08880018.2018.1532478

M3 - Article

C2 - 30681039

AN - SCOPUS:85060596889

VL - 35

SP - 316

EP - 321

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

SN - 0888-0018

IS - 5-6

ER -